Introduction
============

Chronic kidney disease (CKD) is a common chronic condition that is considered a risk factor for development of cardiovascular disease \[[@b1-krcp-38-196],[@b2-krcp-38-196]\]. To prevent development of CKD, various risk factors, including hypertension and diabetes, must be controlled. When controlling these risk factors, several medications are needed, which have potential side effects and contribute to increased socioeconomic burden \[[@b3-krcp-38-196]--[@b5-krcp-38-196]\]. Therefore, other modifiable risk factors must be identified.

Hydration status is defined as the balance between water input and output \[[@b6-krcp-38-196]\]. Excess output or insufficient input of water causes dehydration. Generally, dehydration is thought to have harmful renal effects, causing acute kidney injury \[[@b7-krcp-38-196],[@b8-krcp-38-196]\] or chronic kidney damage \[[@b9-krcp-38-196]--[@b11-krcp-38-196]\]. However, if dehydration is mild and persistent, the effect of dehydration on kidney function is complicated. To date, there has been substantial evidence demonstrating that mild dehydration causes renal hyperfiltration, as shown in high protein intake cases \[[@b12-krcp-38-196]\]. Although the exact mechanisms have not been fully elucidated, recent studies have suggested that increased vasopressin in dehydrated individuals may play a central role in dehydration-associated hyperfiltration \[[@b13-krcp-38-196]\].

Improving hydration status and reducing vasopressin and associated hyperfiltration may be a good strategy for controlling CKD \[[@b13-krcp-38-196]\]. Although several studies have attempted to demonstrate the benefits of improving hydration and reducing risk related to CKD \[[@b14-krcp-38-196]--[@b20-krcp-38-196]\], the results were inconsistent and therefore not conclusive. One limitation of previous studies was that they mostly used water intake for hydration status. Water intake is a poor hydration marker since it does not measure output. It is necessary to measure both water intake and output simultaneously to obtain a precise hydration marker and to appropriately reflect hydration status. In this regard, urine specific gravity may be a more suitable hydration marker, particularly in a large population study \[[@b6-krcp-38-196]\]. Although there have been many animal and human studies in regards to dehydration-associated hyperfiltration, it has never been assessed at a population level. Therefore, we used data from the Korea National Health and Nutrition Examination Survey (KNHANES) to identify the relationship between hydration status and kidney function in a large-scale ambulatory sample of community-dwelling Korean adults.

Methods
=======

Participants
------------

Since 1998, KNHAHES has been performed periodically to assess the health and nutritional status of the civilian, non-institutionalized Korean population. The population subject to the KNHANES includes citizens of the Republic of Korea and excludes nursing home residents, servicepersons, prisoners, and foreigners. Participants were selected using proportional allocation systematic sampling with multistage stratification. Details of the sample design can be found elsewhere \[[@b21-krcp-38-196]\]. This study used data from KNHANES 2008 to 2011 and 2014 to 2015. Of the 65,983 candidates, 52,683 agreed to participate in KNHANES 2008 to 2011 and 2014 to 2015 (participation rate of 79.7%). The protocol was comprised of a health-questionnaire survey, health examination, and nutrition survey. The nutrition survey was conducted by visiting the subject's house. Health questionnaire surveys and health examinations were conducted using mobile examination vehicles. The study protocol was in accordance with the Declaration of Helsinki. The Institutional Review Board of the Korea Centers for Disease Control approved the study (IRB numbers: 2008-04EXP-01-C, 2009-01CON-03-2C, 2010-02CON-21-C, 2011-02CON-06-C, and 2013-12-EXP-03-5C). Written informed consent was obtained from all subjects. Of the 52,683 participants, 24,341 were excluded. Excluded participants consisted of 1,778 participants assessed in a different central laboratory, 12,417 age \< 20 years, 4,653 missing a urine specific gravity test, 1,033 missing blood urea nitrogen and creatinine tests, and 4,460 missing urine sodium and creatinine tests. In total, 28,342 participants were included in the final analysis ([Supplementary Fig. 1](#s1-krcp-38-196){ref-type="supplementary-material"}).

Data collection and measurements
--------------------------------

Standardized interviews were conducted in participant houses in order to collect information on demographic variables, medical history, medication use, and a variety of other health-related variables. Blood pressure (BP) was measured three times in accordance with a standard protocol, and the mean value of the three measurements was used as the representative BP. Height was measured to the nearest 0.1 cm using a portable stadiometer (Seriter, Bismarck, USA). Weight was measured to the nearest 0.1 kg using a Giant-150N calibrated balance-beam scale (Hana, Seoul, Korea). Body mass index was calculated by dividing the weight of the participant by the height squared (kg/m^2^). Waist circumference was measured with a tape measure (Seca 200; Seca, Hamburg, Germany) to the nearest 0.1 cm at the midpoint between the lower border of the rib cage and the highest point of the iliac crest. Fasting blood samples and spot urine samples collected from each participant were processed, refrigerated immediately, and transported in cold storage to a central laboratory (Neodin Medical Institute, Seoul, Korea). Total cholesterol, fasting blood glucose, blood urea nitrogen, serum and urinary creatinine, and urinary sodium levels were measured using the Hitachi Automatic Analyzer 7600 (Hitachi, Tokyo, Japan). Urine specific gravity and protein were measured by a dipstick method using the UriSys 2400 analyzer (Roche, Mannheim, Germany). The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation \[[@b22-krcp-38-196]\].

Definitions
-----------

Hypertension was defined as systolic BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg, treatment with anti-hypertensive drugs, or previous diagnosis by a physician. Diabetes was defined as fasting plasma glucose ≥ 6.94 mmol/L, any treatments with insulin or oral anti-diabetic drugs, or previous diagnosis by a physician. Dyslipidemia was defined as total cholesterol ≥ 6.22 mmol/L, treatment with dyslipidemic drugs, or previous diagnosis by a physician. Cardiovascular disease was defined as cerebrovascular attack or coronary artery disease. A frequent drinker was defined as an individual who consumed alcoholic beverages two or more times a week. Regular walking was defined as the highest quartile of weekly walking time (≥ 7 hours/week). High water intake was defined as the highest quartile of daily water intake (≥ 1.2 L/day). High eGFR was defined as a median value of 95.24 mL/min/1.73 m^2^ or more. Urine specific gravity unit (SGU) was calculated using the following equation: SGU = (urine specific gravity − 1.0) × 100 \[[@b23-krcp-38-196]\]. Proteinuria was defined as protein level ≥ 1+ on a dipstick urinalysis test.

Statistical analysis
--------------------

Continuous and categorical variables were expressed as mean ± standard deviation (SD) and percentages, respectively. A *P* value was assessed using a one-way analysis of variance (ANOVA) for continuous variables and a linear-by-linear association for categorical variables. Differences between multiple groups were analyzed using Bonferroni *post-hoc* analysis for continuous variables and the chi-squared test for categorical variables. The association between urine SGU and eGFR was analyzed via linear regression analysis. The relationship between urine SGU and high eGFR was investigated via logistic regression analysis. In the multivariate analysis, covariates were chosen based on clinical and statistical relevance. For potential non-linear associations between urine SGU and eGFR, the generalized additive model (GAM) for Gaussian distributions was adapted in order to visualize the association between urine SGU and eGFR after adjusting for the same variables used in the multivariate linear regression analysis. We used Akaike's information criterion (AIC) as the primary measure of model fit \[[@b24-krcp-38-196]\]. In the AIC analysis, lower scores within the data set indicated a better model fit, and a urine SGU with the lowest AIC value was assumed to be the threshold value. A *P* value less than 0.05 was considered statistically significant. The relationship between urine SGU and high eGFR was plotted with the penalized smoothing spline method, using the "pspline" package in R statistical software version 3.0.3 (R Foundation for Statistical Computing, Vienna, Austria). All analyses, unless otherwise specified, were performed using SPSS version 22 (IBM Corp., Armonk, USA).

Results
=======

The baseline characteristics of the study participants according to urine SGU quartiles are shown in [Table 1](#t1-krcp-38-196){ref-type="table"}. The median eGFR, proportion of men, and the numbers of current and frequent alcohol drinkers increased as the urine SGU quartile increased. On the other hand, participant age, prevalence of hypertension, diabetes, dyslipidemia, and cardiovascular disease decreased as the urine SGU quartile increased. Proteinuria was positively associated with urine SGU quartile. The mean and SD of eGFR and USG were 94.6 ± 294.6 mL/min/1.73 m^2^ (range, 3.3--146.9 mL/min/1.73 m^2^; interquartile range \[IQR\], 22) and 1.018 ± 0.000 (range, 1.000--1.048; IQR, 0.008), respectively.

The association between urine SGU and eGFR was explored ([Table 2](#t2-krcp-38-196){ref-type="table"}). Univariate linear regression analysis showed eGFR significantly increased as urine SGU increased. In the multivariate linear regression analysis adjusted for variables related to eGFR in the univariate analysis, urine SGU was still positively associated with eGFR. To identify a possible non-linear relationship, we performed a multivariate GAM plot and identified a J-shaped association between urine SGU and eGFR with the lowest AIC observed when the urine SGU was 1.2 ([Fig. 1](#f1-krcp-38-196){ref-type="fig"}).

We analyzed the association between urine SGU and high eGFR. The odds ratio (OR) and 95% confidence interval (CI) for a 1 unit increase in urine SGU for high eGFR was 1.432 (1.376--1.491, *P* \< 0.001) using univariate logistic regression analysis. Multivariate analysis adjusted for age, sex, systolic and diastolic BP, pulse rate, diabetes, dyslipidemia, cardiovascular disease, waist circumference, proteinuria, smoking and alcohol drinking habits, urine sodium and creatinine, and high water intake showed the OR (95% CI) per 1 unit increase of urine SGU for high eGFR was 2.570 (2.289--2.886, *P* \< 0.001). We also performed subgroup analysis and observed the same results regardless of gender, age, water intake, diabetes, and hypertension ([Supplementary Fig. 2](#s1-krcp-38-196){ref-type="supplementary-material"}). As the SGU quartile increased, the OR for high eGFR increased ([Fig. 2](#f2-krcp-38-196){ref-type="fig"}). In the penalized spline curve analysis, we identified a relationship between urine SGU and high eGFR. As a result, the OR for high eGFR steadily increased as the urine SGU quartile increased ([Fig. 3](#f3-krcp-38-196){ref-type="fig"}). We analyzed the factors associated with the highest urine SGU quartile using multivariate logistic regression analysis ([Supplementary Table 1](#s1-krcp-38-196){ref-type="supplementary-material"}). Futher details on [Supplementary materials](#s1-krcp-38-196){ref-type="supplementary-material"} are presented online (available at: <https://doi.org/10.23876/j.krcp.18.0147>).

We explored the cardio-metabolic effect of urine SGU ([Table 3](#t3-krcp-38-196){ref-type="table"}). Increased urine SGU was independently associated with decreased systolic and diastolic BP and pulse rate. Although increased urine SGU was associated with decreased waist circumference, it was independently associated with increased fasting glucose and total cholesterol levels.

Discussion
==========

It is known that severe dehydration can cause pre-renal acute kidney injury. Profound and prolonged dehydration can also contribute to increased risk of CKD \[[@b11-krcp-38-196]\]. Paradoxically, mild and sub-morbid dehydration causes hyperfiltration, which has been associated with increased vasopressin levels \[[@b13-krcp-38-196]\]. Thus, as a rationale for a low protein diet \[[@b25-krcp-38-196]\], improving hydration status aims not only to increase renal perfusion but also to limit dehydration-associated hyperfiltration. In this regard, improving hydration status may be another modifiable factor to control CKD and should be studied further. Until recently, there have been several studies \[[@b14-krcp-38-196]--[@b20-krcp-38-196]\] that have investigated the effect of improving hydration status on CKD progression. However, the results have been inconsistent and no significant benefit of improving hydration status has been demonstrated. This may be due to previous studies \[[@b14-krcp-38-196]--[@b17-krcp-38-196],[@b19-krcp-38-196],[@b20-krcp-38-196]\] using water intake only, which would not reflect actual hydration status since water output was not been considered. Since urine specific gravity is an easy and reliable hydration marker, especially in a large population \[[@b6-krcp-38-196]\], we conducted the current study to identify the relationship between urine SGU, a unit derived from urine specific gravity, and eGFR in a large-scale sample of ambulatory community-dwelling Korean adults.

In this study, increased urine SGU was associated with increased eGFR. This was independent of several confounders in the multivariate linear regression analysis, which included demographics, comorbidities, and behavioral patterns. In addition, we identified a J-shaped association between urine SGU and eGFR, with a definite threshold value of 1.2 (specific gravity of 1.012), in the multivariate GAMs plot. Since the study only included ambulatory community-dwelling adults, it was reasonable to classify dehydration in this population as sub-morbid dehydration. To our knowledge, this was the first study to demonstrate that hyperfiltration was associated with sub-morbid dehydration in a population-based data set.

In the current analysis, increased urine SGU quartile was associated with increased OR for high eGFR. Penalized spline curve analysis shows a nonlinear relationship between urine SGU and the OR for high eGFR. As a result, the odds for high eGFR steadily increased as urine SGU increased. Interestingly, the results were consistent with the results of Anastasio et al \[[@b26-krcp-38-196]\]. In their study, participants with high hydration showed an inverse relationship between urine osmolality and inulin clearance (r = −0.237). On the other hand, increased urine osmolality was positively associated with inulin clearance (r = 0.703) in participants with low hydration \[[@b26-krcp-38-196]\].

To date, the clinical meaning of dehydration-associated hyperfiltration is uncertain. In this study, increased SGU was associated with increased fasting glucose and total cholesterol, which is similar to the metabolic risk of copeptin. Copeptin is derived from the arginine vasopressin precursor and is a marker of vasopressin, which is positively correlated with insulin resistance, obesity, metabolic syndrome, and diabetes mellitus \[[@b27-krcp-38-196]--[@b32-krcp-38-196]\]. Increased copeptin has a deleterious effect in individuals who have conditions such as diabetic nephropathy and salt-sensitive hypertension \[[@b12-krcp-38-196]\]. Therefore, we postulated that dehydration-associated hyperfiltration may have a detrimental renal effect and should be treated meticulously to reduce CKD-associated risks, for instance high protein intake-associated hyperfiltration \[[@b25-krcp-38-196],[@b33-krcp-38-196],[@b34-krcp-38-196]\].

The present study has several limitations. First, a causal relationship could not be accurately identified, and since this is a cross-sectional study, the results need to be interpreted cautiously. However, while this was a cross-sectional study, new hypotheses can be made. The study was based on a large-scale general population, and due to the participant number, we found potential beneficial cardiovascular effects (decreased BP and pulse rate) for sub-morbid dehydration. Therefore, future prospective interventional studies are needed to determine whether the cardiovascular effect of sub-morbid dehydration is beneficial. Second, other hydration indices, such as the results of a bioimpedance analysis, were not used. In addition, other biomarkers, such including copeptin or uric acid, could not be analyzed since KNHANES was not primarily designed to identify the association between hydration status and kidney function. Even after 8 hours of fasting, we only obtained a measure of urine specific gravity, which is a limitation of this study. Finally, the generalizability of the results is limited because the study was conducted within a single country with a single ethnic population.

In conclusion, sub-morbid dehydration was associated with higher kidney function. Future studies are needed to confirm our study results and to identify the clinical meaning of dehydration-associated hyperfiltration.
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![GAM plot between urine SGU and eGFR\
Upper (≥ 3.0) and lower (\< 0.5) one percent of urine SGU were truncated. The dashed line indicates 95% confidence intervals for the smoothed eGFR values using the multivariate GAM analysis adjusted for age, sex, systolic and diastolic blood pressure, pulse rate, diabetes, dyslipidemia, cardiovascular disease, waist circumference, proteinuria, smoking and alcohol drinking habits, urine sodium and creatinine, and high water intake.\
AIC, Akaike's information criterion; eGFR, estimated glomerular filtration rate; GAM, generalized additive model; SGU, specific gravity unit.](krcp-38-196f1){#f1-krcp-38-196}

![Odds ratio (OR) of urine SGU quartiles for high eGFR\
Black bar graphs represent the percentage of patient with low eGFR. Red square dots represent OR and red bars represent the 95% confidence interval (CI) using multivariate logistic analysis adjusted for age, sex, systolic and diastolic blood pressure, pulse rate, diabetes, dyslipidemia, cardiovascular disease, waist circumference, proteinuria, smoking and alcohol drinking habits, urine sodium and creatinine, and high water intake.\
eGFR, estimated glomerular filtration rate; Ref., reference; SGU, specific gravity unit.](krcp-38-196f2){#f2-krcp-38-196}

![Penalized smoothing splines showing the relationship between urine SGU and high eGFR\
Upper (≥ 3.0) and lower one percent (\< 0.5) of urine SGU were truncated. The red line indicates the odds ratio (OR) and the black dotted line indicates the 95% confidence interval (CI) for the urine SGU that influences high eGFR. OR and 95% CI were analyzed using logistic regression analysis. In multivariate analysis, covariates were age, sex, systolic and diastolic blood pressure, pulse rate, diabetes, dyslipidemia, cardiovascular disease, waist circumference, proteinuria, smoking and alcohol drinking habits, urine sodium and creatinine, and high water intake.\
eGFR, estimated glomerular filtration rate; SGU, specific gravity unit.](krcp-38-196f3){#f3-krcp-38-196}

###### 

Baseline characteristics of the study population according to urine SGU quartile status

  Characteristic               Quartile of urine SGU   *P*-trend                                                                                                                                                                           
  ---------------------------- ----------------------- --------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------- ----------
  Age (yr)                     53.8 ± 15.5             55.1 ± 15.5[a](#tfn5-krcp-38-196){ref-type="table-fn"}    52.1 ± 15.4[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}    44.9 ± 15.4[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}    \< 0.001
  Sex, male (%)                29.9                    40.4[a](#tfn5-krcp-38-196){ref-type="table-fn"}           48.1[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}           54.6[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}           \< 0.001
  Current smoker (%)           15.2                    17.1[a](#tfn5-krcp-38-196){ref-type="table-fn"}           22.3[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}           26.9[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}           \< 0.001
  Frequent drinker (%)         16.0                    19.5[a](#tfn5-krcp-38-196){ref-type="table-fn"}           25.2[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}           24.9[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}             \< 0.001
  Regular walking (%)          27.0                    26.6                                                      26.5                                                        27.0                                                          0.820
  Hypertension (%)             38.0                    40.6[a](#tfn5-krcp-38-196){ref-type="table-fn"}           34.4[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}           26.1[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}           \< 0.001
  Diabetes (%)                 12.6                    13.3                                                      10.3[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}           9.9[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}              \< 0.001
  Dyslipidemia (%)             20.8                    21.4                                                      19.1[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}           15.8[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}           \< 0.001
  Cardiovascular disease (%)   5.0                     5.6                                                       4.7[b](#tfn5-krcp-38-196){ref-type="table-fn"}              2.8[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}            \< 0.001
  BMI (kg/m^2^)                23.5 ± 3.2              23.8 ± 3.3[a](#tfn5-krcp-38-196){ref-type="table-fn"}     23.8 ± 3.4[a](#tfn5-krcp-38-196){ref-type="table-fn"}       23.9 ± 3.5[a](#tfn5-krcp-38-196){ref-type="table-fn"}         0.008
  Waist circumference (cm)     80.8 ± 9.5              82.0 ± 9.7[a](#tfn5-krcp-38-196){ref-type="table-fn"}     82.1 ± 9.8[a](#tfn5-krcp-38-196){ref-type="table-fn"}       81.8 ± 10.3[a](#tfn5-krcp-38-196){ref-type="table-fn"}        0.025
  Systolic BP (mmHg)           122.3 ± 18.9            123.0 ± 18.6                                              120.7 ± 16.8[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}   117.1 ± 15.5[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}   \< 0.001
  Diastolic BP (mmHg)          76.2 ± 10.7             76.8 ± 10.7                                               76.8 ± 10.4                                                 76.3 ± 10.3                                                   0.608
  Pulse rate (counts/min)      69.9 ± 9.2              69.9 ± 9.3                                                70.1 ± 9.3                                                  70.4 ± 9.8                                                    0.002
  Fasting glucose (mmol/L)     5.44 ± 1.11             5.50 ± 1.12                                               5.46 ± 1.11                                                 5.54 ± 1.60[a,c](#tfn5-krcp-38-196){ref-type="table-fn"}      \< 0.001
  Total cholesterol (mmol/L)   4.90 ± 0.93             4.91 ± 0.94                                               4.93 ± 0.93                                                 4.88 ± 0.93[c](#tfn5-krcp-38-196){ref-type="table-fn"}        0.488
  eGFR (mL/min/1.73 m^2^)      92.9 ± 18.2             91.0 ± 17.9[a](#tfn5-krcp-38-196){ref-type="table-fn"}    93.7 ± 16.3[b](#tfn5-krcp-38-196){ref-type="table-fn"}      98.4 ± 15.9[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}    \< 0.001
   ≥ 90 (%)                    60.3                    55.0[a](#tfn5-krcp-38-196){ref-type="table-fn"}           61.3[b](#tfn5-krcp-38-196){ref-type="table-fn"}             70.9[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}           \< 0.001
   60--90 (%)                  34.7                    39.5[a](#tfn5-krcp-38-196){ref-type="table-fn"}           35.7[b](#tfn5-krcp-38-196){ref-type="table-fn"}             27.8[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}           \< 0.001
   30--60 (%)                  4.4                     5.2[a](#tfn5-krcp-38-196){ref-type="table-fn"}            2.9[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}            1.3[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}            \< 0.001
   \< 30 (%)                   0.6                     0.3[a](#tfn5-krcp-38-196){ref-type="table-fn"}            0.1[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}            0.0[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}            \< 0.001
  BUN (mmol/L)                 4.7 ± 1.8               5.1 ± 1.5[a](#tfn5-krcp-38-196){ref-type="table-fn"}      5.2 ± 1.5[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}      5.5 ± 1.5[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}      \< 0.001
  Serum creatinine (μmol/L)    71.2 ± 30.5             73.4 ± 23.3[a](#tfn5-krcp-38-196){ref-type="table-fn"}    73.4 ± 16.4[a](#tfn5-krcp-38-196){ref-type="table-fn"}      74.5 ± 15.3[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}    \< 0.001
  Urine SGU                    1.0 ± 0.2               1.5 ± 0.1[a](#tfn5-krcp-38-196){ref-type="table-fn"}      1.9 ± 0.1[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}      2.5 ± 0.3[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}      \< 0.001
  Urine sodium (mmol/L)        81.1 ± 36.3             123.3 ± 42.6[a](#tfn5-krcp-38-196){ref-type="table-fn"}   140.0 ± 48.6[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}   137.7 ± 51.9[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}     \< 0.001
  Urine creatinine (mmol/L)    5.1 ± 2.1               9.0 ± 2.9[a](#tfn5-krcp-38-196){ref-type="table-fn"}      13.0 ± 4.0[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}     19.6 ± 6.9[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}     \< 0.001
  Urine sodium to creatinine   18.7 ± 11.9             15.7 ± 8.7[a](#tfn5-krcp-38-196){ref-type="table-fn"}     12.3 ± 7.3[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}     8.3 ± 5.1[a,b,c](#tfn5-krcp-38-196){ref-type="table-fn"}      \< 0.001
  High water intake (%)        34.4                    29.6[a](#tfn5-krcp-38-196){ref-type="table-fn"}           27.6[a](#tfn5-krcp-38-196){ref-type="table-fn"}             27.9[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}             \< 0.001
  Proteinuria (%)              0.7                     1.4[a](#tfn5-krcp-38-196){ref-type="table-fn"}            1.1[a,b](#tfn5-krcp-38-196){ref-type="table-fn"}            1.4[a](#tfn5-krcp-38-196){ref-type="table-fn"}                0.002

Data are presented as mean ± standard deviation for continuous variables and a percentage for categorical variables.

Conversion factor from conversional unit to SI unit was in × 0.0555 in glucose, × 0.0259 in cholesterol, × 0.357 in BUN, and × 88.4 in serum and urine creatinine, respectively.

BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; SGU, specific gravity unit.

*P* value was analyzed by the linear-term of a one-way ANOVA for continuous variables and a linear-by-linear association for categorical variables.

are defined as *P* = 0.008 when compared to the \< 1.4, 1.4 to 1.8, and 1.8 to 2.2 groups, respectively, with a Bonferroni *post-hoc* analysis of one-way ANOVA for continuous variables and a chi-squared test for categorical variables.

###### 

Factors associated with estimated glomerular filtration rate

  Factor                                     Univariate                     Multivariate                                
  ------------------------------------------ ------------------------------ -------------- ---------------------------- ----------
  Urine SGU (per 1 unit increase)            4.169 (3.838 to 4.505)         \< 0.001       5.334 (4.866 to 5.802)       \< 0.001
  Age (per 1 yr increase)                    −0.757 (−0.766 to −0.749)      \< 0.001       −0.776 (−0.788 to −0.764)    \< 0.001
  Male (yes vs. no)                          −5.095 (−5.492 to −4.698)      \< 0.001       −4.636 (−5.009 to −4.264)    \< 0.001
  Hypertension (yes vs.no)                   −13.202 (−13.922 to −13.128)   \< 0.001       --                           --
  Systolic BP (per 1 mmHg increase)          −0.341 (−0.352 to −0.330)      \< 0.001       0.024 (0.011 to 0.038)       0.169
  Diastolic BP (per 1 mmHg increase)         −0.163 (−0.182 to −0.144)      \< 0.001       −0.053 (−0.074 to −0.033)    \< 0.001
  Diabetes (yes vs. no)                      −11.574 (−12.198 to −10.949)   \< 0.001       −1.595 (−2.097 to −1.093)    \< 0.001
  Dyslipidemia (yes vs. no)                  −8.040 (−8.549 to−7.532)       \< 0.001       −1.233 (−1.622 to −0.843)    \< 0.001
  Waist circumference (per 1 cm increase)    −0.435 (−0.4545 to −0.415)     \< 0.001       −0.062 (−0.079 to −0.046)    \< 0.001
  Proteinuria (yes vs. no)                   −16.056 (−17.877 to −14.235)   \< 0.001       −9.030 (−10.383 to −7.678)   \< 0.001
  Cardiovascular disease (yes vs. no)        −17.105 (−18.083 to −16.128)   \< 0.001       −3.266 (−4.001 to −2.531)    \< 0.001
  Pulse rate (per 1 count/min increase)      0.174 (0.152 to 0.195)         \< 0.001       0.057 (0.041 to 0.072)       \< 0.001
  Current smoker (yes vs. no)                2.306 (1.816 to 2.796)         \< 0.001       1.274 (0.858 to 1.689)       \< 0.001
  Frequent drinker (yes vs. no)              0.627 (0.142 to 1.113)         0.011          2.265 (1.878 to 2.653)       \< 0.001
  Urine sodium (per 1 mmol/L increase)       0.011 (0.007 to 0.015)         \< 0.001       0.007 (0.004 to 0.011)       \< 0.001
  Urine creatinine (per 1 mmol/L increase)   0.263 (0.236 to 0.290)         \< 0.001       −0.614 (−0.652 to −0.577)    \< 0.001
  High water intake (yes vs. no)             2.118 (1.650 to 2.586)         \< 0.001       0.546 (0.217 to 0.874)       \< 0.001

Beta and 95% confidence interval (CI) were analyzed by linear regression analysis. In the multivariate analysis, all of the statistically and clinically significant variables above were used as covariates.

BP, blood pressure; SGU, specific gravity unit; --, not included in the model.

###### 

Association between urine SGU and cardio-metabolic derangements

  Variable              Per 1 unit increase of urine SGU   
  --------------------- ---------------------------------- ----------
  Systolic BP           −1.859 (−2.327 to −1.392)          \< 0.001
  Diastolic BP          −1.859 (−2.327 to −1.392)          \< 0.001
  Pulse rate            −0.888 (−1.292 to −0.484)          \< 0.001
  Waist circumference   −0.481 (−0.856 to −0.106)          0.012
  Fasting glucose       1.255 (1.208 to 1.302)             \< 0.001
  Total cholesterol     0.103 (0.065 to 0.142)             \< 0.001

Beta and 95% confidence interval (CI) were analyzed using multivariate linear regression analysis with the following covariates: systolic and diastolic blood pressure (BP), pulse rate, fasting glucose, total cholesterol, waist circumference, age, sex, proteinuria, cardiovascular disease, smoking and drinking status, high water intake, and urine sodium and creatinine. When covariates were chosen as dependent variables, they were excluded from the model.

SGU, specific gravity unit.

[^1]: Edited by Soo Wan Kim, Chonnam National University Medical School, Gwangju, Korea
